A Single Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Zibotentan in Healthy Participants Compared to Participants With Moderate Hepatic and Moderate Renal Impairment
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Zibotentan (Primary)
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 26 Jan 2022 Status changed from recruiting to completed.
- 26 Nov 2021 Status changed from not yet recruiting to recruiting.
- 12 Nov 2021 New trial record